Aurobindo Pharma Limited — Important, 28-12-2024: Updates

Aurobindo Pharma received a warning letter from the National Stock Exchange (NSE) concerning a breach related to corporate announcements that mistakenly included the company's Permanent Account Number (PAN). The NSE emphasized that disclosing PAN information in any public document is against exchange regulations. This violation is regarded as serious, with the NSE urging the company to implement corrective measures to prevent future occurrences. Investors should watch closely for Aurobindo's compliance actions, as any subsequent infractions could lead to further consequences and impact the company's reputation.